| By PR Newswire |
Article Rating: |
|
| February 25, 2013 05:00 AM EST |
Reads: |
125 |
NANJING, China, Feb. 25, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012 on Thursday, March 7, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, March 7 at 9 p.m. Beijing/Hong Kong time).
To access the conference call, please dial:
|
International toll:
|
+65.6723.9381
|
|
United States toll-free:
|
+1.866.519.4004
|
|
United States toll:
|
+1.718.354.1231
|
|
China Domestic toll-free:
|
800.819.0121
|
|
China Domestic mobile toll-free:
|
400.620.8038
|
|
Hong Kong toll:
|
+852.2475.0994
|
Please ask to be connected to Q4 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 12783585.
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.
Following the earnings conference call, an archive of the call will be available by dialing:
|
United States toll-free:
|
+1.855.452.5696
|
|
United States toll:
|
+1.646.254.3697
|
The passcode for replay participants is 12783585. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
|
In Nanjing:
|
|
|
|
|
In the United States:
|
|
Jie Liu D'Elia
|
|
|
|
Cindy Zheng
|
|
|
Vice President
|
|
|
|
Brunswick Group
|
|
|
Simcere Pharmaceutical Group
|
|
|
Tel: 1-212-333-3810
|
|
Tel: 86-25-8556-6666*8857
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In Beijing:
|
|
|
|
|
|
|
|
|
Yue Yu
|
|
|
|
|
|
|
|
|
Brunswick Group
|
|
|
|
|
|
|
|
Tel: 86-10-5960-8600
|
|
|
|
|
|
|
SOURCE Simcere Pharmaceutical Group
